HYBIO PHARMACEUTICAL CO. LTD.

China

Factory icon Manufacturer/ Producer

HYBIO PHARMACEUTICAL CO. LTD.
Web icon

China

ASMF: Ganirelix, Atosiban,Terlipressin CEP: Leuprorelin, Desmopressin, Oxytocin, Octreotide US DMF: Eptifibitide, Liraglutide, Ganirelix, Glatiramer, Desmopressin, LInaclotide, Nesiritide, Teriparatide. R&D: Semaglutide, Degarelix, Goserelin, Ziconotide etc.

Request for a quote

China

CAS: 123246-29-7 Molecular Weight: 1570.32 Chemical Formula: C80H113ClN18O13 Drug substance / API: US DMF (30800) ready; EU ASFM ready; EU WC certificate.

Request for a quote

China

CAS: 53714-56-0 Molecular Weight: 1209.4 Chemical Formula: C59H84N16O12 Drug substance / API: EU CEP certificate ready.

Request for a quote

China

US DMF + KDMF+ WC CAS: 16679-58-6 Formula: C46H64N14O12S2

Request for a quote

Founded in 1998, Hybio is a leading peptide pharmaceutical company and the first going public in China (2011, stock code 300199). We offer a full range of peptide products (API & FDF) and services (CRO & CDMO). Hybio Group currently owns 8 subsidiaries and branches, with its Wuhan subsidiary as an API production base, Pingshan branch as a FDF production base, Changee subsidiary as a medical device base, Dali Biotech subsidiary as hemp processing base etc... Hybio Headquarters in Shenzhen has passed local & national NMPA GMP inspection for over 90 times, overseas FDA, EU, ANVISA, KFDA (etc.) GMP inspections for 8 times and customer audits for over 50 times. It owns over 300 invention patents and 102 PCTs, with more than 100 patents authorized. Hybio Wuhan subsidiary is a specialized peptide API manufacturing base, which was put into production in 2019. The full capacity for peptide API can be up to 1000kg/year and the current capacity is around 300kg/year. Main APIs are Liraglutide, Semaglutide, Tirzepatide, Glatiramer, Ganirelix, Cetrorelix, Degarelix, Atosiban, Oxytocin, Carbetocin, Terlipressin, Desmopressin, Linaclotide, Plecanatide, Leuprorelin, Triptorelin, Teriparatide, Eptifibatide, Octreotide, Lanreotide, Somatostatin, etc.

Latest company news

Octreotide Acetate, passed NMPA evaluation

Octreotide Acetate, passed NMPA evaluation

Award of a new certification ・ 31 Aug 2022 read more Open In New icon

Another API of Hybio Wuhan site, Octreotide Acetate, has passed the evaluation of Chinese NMPA! This API can be used in FDF commercial production for marketing. Great work for our Wuhan team! For their unremitting efforts since the operation of the site in 2019! We look forward to have more approvals soon. EU CEP is ready too! Your inquiries are welcome as always!

Documents

Domain icon Manufacturer/ Producer

HYBIO PHARMACEUTICAL CO. LTD.

Hybio Innovation Industry Building, No. 7, Guansheng 4th RD

Guanlan high-tech park, longhua district

518110 Shenzhen - China

Contact

Company info

Key figures

  • Company headcount
    > 500

Organisation

  • Year established
    1998
  • pages.epage-home.site-status
    Registered office – Parent company
  • Main activity
    Manufacturer/ Producer

Business info

Trading areas

  • Check Circle Outline icon International

Delivery areas

Activities of HYBIO PHARMACEUTICAL CO. LTD.

  • Pharmaceutical products
Office Building Outline icon
A page for your business
Can you see this? Your potential clients will too. Join us now so you too can be visible on europages

Request for quotes

Create one request and get multiple quotes form verified suppliers.

  • Only relevant suppliers
  • Data privacy compliant
  • 100% free